Table A5. Sensitivity analyses of indirect comparisons: Symptomatic venous thromboembolism, clinically relevant bleeding and net clinical endpoint using the fixed effects model.

OUTCOME	RIV vs. DAB	API vs. DAB	RIV vs. API
	RR (95%CI)	RR (95%CI)	RR (95%CI)
Symptomatic venous thromboembolism	0.53 (0.29 to 0.99)	1.05 (0.53 to 2.05)	0.51 (0.27 to 0.96)
Clinically relevant bleeding	1.12 (0.87 to 1.43)	0.73 (0.57 to 0.93)	1.54 (1.21 to 1.95)
Net clinical endpoint	0.92 (0.65 to 1.30)	0.95 (0.63 to 1.42)	0.97 (0.67 to 1.39)

API = apixaban; CI = confidence interval; DAB = dabigatran; RIV = rivaroxaban; RR = relative risk.

Table A6. Sensitivity analyses of indirect comparisons: Symptomatic venous thromboembolism, clinically relevant bleeding and net clinical endpoint excluding phase II trials.

OUTCOME	RIV vs. DAB	API vs. DAB	RIV vs. API
	RR (95%CI)	RR (95%CI)	RR (95%CI)
Symptomatic venous thromboembolism	0.47 (0.25 to 0.88)	1.14 (0.57 to 2.27)	0.41 (0.21 to 0.80)
Clinically relevant bleeding	1.12 (0.87 to 1.44)	0.73 (0.56 to 0.93)	1.54 (1.20 to 1.96)
Net clinical endpoint	0.91 (0.64 to 1.29)	0.94 (0.62 to 1.41)	0.97 (0.67 to 1.40)

API = apixaban; CI = confidence interval; DAB = dabigatran; RIV = rivaroxaban; RR = relative risk.

Table A7. Symptomatic venous thromboembolism, clinically relevant bleeding and net clinical endpoint excluding the RECORD-2 study.

OUTCOME	RIV vs. DAB	API vs. DAB	RIV vs. API
	RR (95%CI)	RR (95%CI)	RR (95%CI)
Symptomatic venous thromboembolism	0.61 (0.32 to 1.17)	1.16 (0.31 to 4.28)	0.59 (0.32 to 1.07)
Clinically relevant bleeding	1.12 (0.87 to 1.45)	0.73 (0.57 to 0.94)	1.55 (1.21 to 1.99)
Net clinical endpoint	0.98 (0.68 to 1.41)	0.99 (0.61 to 1.61)	1.03 (0.71 to 1.51)

API = apixaban; CI = confidence interval; DAB = dabigatran; RIV = rivaroxaban; RR = relative risk.